pipette
ESEspañol

MHCII+ cancer-associated fibroblasts promote antitumor immunity in pancreatic cancer

J. Hung, S. Silveria-Davies, J. Vickery, B. G. Maker, C. Mikolajczyk, D. S. Axe, B. M. Weist, J. E. Elias, M. DuPage

Preprint

In the authors' words

The functions of major histocompatibility complex class II molecule-expressing cancer-associated fibroblasts (MHCII+CAFs) in pancreatic cancer remain controversial. MHCII+CAFs are primarily described as immunosuppressive, as MHCII allows for direct interaction with, and support of, regulatory T cells (Tregs). However, MHCII+CAF functions may be more complex depending on their origins and their cellular interactions within the tumor microenvironment. Here, using orthotopic models of pancreatic cancer, we show that conventional CD4+ T cells and their production of Interferon gamma (IFN{gamma}) increased MHCII+CAFs in tumors. Acute depletion of Tregs using Foxp3DTR mice revealed that Tregs suppress the abundance of MHCII+CAFs in tumors by inhibiting CD4 T cell responses that can directly control primary tumor growth and metastatic progression. Functionally, MHCII expression on fibroblasts was required for CD4 T cell control of PDAC progression upon Treg ablation. Collectively, our findings identify an IFN{gamma}-driven, antitumor activity of MHCII expression on CAFs and reveal that CAFs may be harnessed to promote adaptive immunity to PDAC.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 5. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.03.764075